Pembrolizumab (NSCLC, neoadjuvant + adjuvant) – Second Addendum to Project A24-46

Report documents

1. Addendum

   Pembrolizumab (NSCLC, neoadjuvant + adjuvant) – Second Addendum to Project A24-46

   published on

   17.10.2024

   Document type

   PDF document, 295 kB, DE, not accessible

   DOI-Link

   https://doi.org/10.60584/G24-23

   Download file : Addendum (PDF document, 295 kB, DE, not accessible)

Additional information

Project details

Project no.

G24-23

Commission

Commission awarded on 10.09.2024 by the Federal Joint Committee (GBA).

Report type

Addendum

Status

Commission completed

Department/Division

Health Economics

Topic

Cancer

Note

If, in the course of the discussions on a commission of the GBA, a need for further revision arises, IQWiG submits an addendum. The GBA decides on the number of patients in the SHI target population.

DOI

https://doi.org/10.60584/G24-23

Connected Projects

1. Dossier assessment

   Pembrolizumab (NSCLC, neoadjuvant + adjuvant) – Benefit assessment according to § 35a Social Code Book V

   Project no.

   A24-46

   Last updated

   17.10.2024

   Status: Commission completed

2. Addendum

   Pembrolizumab (NSCLC, neoadjuvant + adjuvant) – Addendum to Project A24-46

   Project no.

   A24-93

   Last updated

   17.10.2024

   Status: Commission completed